STMN.SW

Premium GrowerAI pick

Straumann Holding AG · Healthcare · Switzerland · $19.1B cap · $54.8M/day traded

CHF 106.85 +1.3% · close 10 Nov · scored 11 Nov

Premium Grower: Strong business with the market behind it, priced at a premium.

Full research report (May 2026), free
78
Score
Get score and insider alerts

After its 28 Oct results, analysts left next year's EPS estimate little changed.

Quality
76
Value
25
Momentum
74

As of 11 Nov 2026, the MoatMap Score for Straumann Holding AG (STMN.SW) is 78/100, ranked against 25,000+ stocks in 38 markets (Quality 76, Value 25, Momentum 74, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
45.2x
peers 34.7x
ROE
17.0%
peers 10.6%
D/E
0.2x
peers 0.4x
Dividend %
0.9%
trailing yield
AI REVIEW

Straumann is the global leader in dental implants, with premium (Straumann) and value (Neodent, Anthogyr) brands plus clear aligners and digital dentistry, giving it a position across every price point that competitors struggle to copy. Dentist training, clinical track record and an installed base of implant systems create real switching costs, returns on capital are high, the balance sheet carries little debt and growth is self-funded. Management has just raised guidance, and insiders, led by the founding family, own about 32% of the company. Implant penetration remains low in most markets, so the reinvestment runway is long, and the business is largely insulated from energy and freight shocks.

ABOUT STRAUMANN HOLDING AG

Read

Straumann Holding AG is a global leader in implant dentistry and aesthetic solutions, providing dental implants, prosthetics, biomaterials, and clear aligners. Its competitive moat is built upon its extensive R&D, clinically proven products, global distribution network, and strong brand reputation among dental professionals. The company holds a dominant market position in premium dental implants, driving innovation and education in oral healthcare.

FINANCIAL SUMMARY (CHF)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue—2.3B2.3B2.5B2.6B3.9%2.7B2.8B3.1B8.3%
EPS (CHF)2.492.731.542.442.23-2.7%2.322.482.9014.0%
Shares—159.4M159.4M159.5M159.5M+0.1%159.5M———
Debt—701.6M412.4M413.9M418.9M-15.8%477.5M———
Equity—1.9B1.8B2.0B2.2B5.3%————
Op CF—415.2M503.9M483.4M504.0M6.7%526.4M———
Inv CF—-434.7M-349.3M-352.6M-273.9M—————
Fin CF—-154.3M-424.4M-169.1M-106.0M—————
PRICE (1Y) · CHF+16.7%
87.892.797.610310730 Sep21 Oct10 Nov
SMA 50SMA 200

Price checkIn an uptrendExperimental

Above its 200-day average and 3% below its 52-week high.

SwingsAverage

Calmer than 70% of stocks we rank over the past year (volatility 31% a year).

How this is worked out

The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
CHF 106.85
RSI (14)
75.6
52-Week Range-2.7% from high
Low CHF 72.22High CHF 109.80

SCORE BREAKDOWN

Quality
76
ROIC
15.6%83.2
ROE
17.0%84.7
GP/Assets
48.6%86.1
Op. Margin
25.1%87.9
FCF/Assets
7.5%79.1
Piotroski
668.8
Int. Cover
30.8x75.4
D/E Ratio
0.21x49.8
Current Ratio
2.26x44.4
Value
25
P/E (TTM)
45.2x22.6
EV/EBITDA
22.2x28.5
P/FCF
55.6x22.1
P/B
7.3x14.8
P/S
6.3x33.8
Div Yield
0.9%36.0
Momentum
74
52W High %
97%95.1
RS 6M
15%73.3
SMA 50/200
1.02x66.3
EPS Rev 4W
+0.5%80.1
EPS Rev 12W
+3.4%77.3
EPS Improve
+68%65.0
Q Growth
6%44.8

FUNDAMENTALS

Market Cap
$19.1B
P/E (Forward)
27.0x
Gross Margin
69.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STMN.SW are excluded.

TickerCompanyMkt CapScore
STMN.SWStraumann Holding AG(you)$19.1B78
ALC.SWAlcon Inc.$34.0B58
YPSN.SWYpsomed Holding AG$6.2B67
TECN.SWTecan Group AG$3.7B67
SKAN.SWSKAN Group AG$2.0B53
CLTN.SWCOLTENE Holding AG$349M74
VBSN.SWIVF Hartmann Holding AG$364M95
SOON.SWSonova Holding AG$20.4B85
MTDMettler-Toledo International Inc.$33.5B71
688235.SSBeOne Medicines AG$61.6B79

Peer medians: ROE 10.6% · P/E 34.7x · Gross margin 58.2%

Company Deep Dive

Read the full report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

View Deep Dive

Straumann Holding AG (STMN.SW): Stock Score Summary

Straumann Holding AG (STMN.SW) has a MoatMap Score of 78/100 based on Quality (76/100), Value (25/100), and Momentum (74/100) factor scores. Straumann is the global leader in dental implants, with premium (Straumann) and value (Neodent, Anthogyr) brands plus clear aligners and digital dentistry, giving it a position across every price point that competitors struggle to copy. Dentist training, clinical track record and an installed base of implant systems create real switching costs, returns on capital are high, the balance sheet carries little debt and growth is self-funded. Management has just raised guidance, and insiders, led by the founding family, own about 32% of the company. Implant penetration remains low in most markets, so the reinvestment runway is long, and the business is largely insulated from energy and freight shocks.

Straumann Holding AG is a global leader in implant dentistry and aesthetic solutions, providing dental implants, prosthetics, biomaterials, and clear aligners. Its competitive moat is built upon its extensive R&D, clinically proven products, global distribution network, and strong brand reputation among dental professionals. The company holds a dominant market position in premium dental implants, driving innovation and education in oral healthcare.

Director dealings

From 2 Mar 2026 to 11 Nov 2026, MoatMap's records hold 3 sales and 6 purchases of Straumann Holding AG (STMN.SW) shares by its directors. The largest: Non-executive board member sold 634,400 shares at CHF 80.56 on 25 Mar 2026 (about CHF 51.1M).

  • 28 Aug 2026: Non-executive board member bought 1,000 shares at CHF 92.86 (about CHF 93K)
  • 27 Aug 2026: Non-executive board member bought 2,200 shares at CHF 92.00 (about CHF 202K)
  • 30 Jun 2026: Executive board / senior management sold 1,100 shares at CHF 106.40 (about CHF 117K)
  • 1 Jun 2026: Executive board / senior management bought 1,050 shares at CHF 94.14 (about CHF 99K)
  • 7 May 2026: Executive board / senior management bought 12,022 shares at CHF 64.56 (about CHF 776K)
STMN.SW insider filings, last 180 days

Key Financial Metrics

PriceCHF 106.85
Market Cap$19.1B
P/E (TTM)45.24
P/E (Forward)27.00
Price/Book7.28
Return on Equity17.0%
Return on Invested Capital15.6%
Debt/Equity0.21x
Gross Margin69.3%
Operating Margin25.1%
Revenue Growth2.3%
Dividend Yield0.9%
Free Cash Flow$344M

Straumann Holding AG operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (Switzerland).

Frequently Asked Questions

What is Straumann Holding AG’s (STMN.SW) MoatMap Score?
The MoatMap Score for Straumann Holding AG (STMN.SW) is 78/100. It is a composite of Quality (76), Value (25), and Momentum (74), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Straumann Holding AG have an economic moat?
Straumann Holding AG (STMN.SW) has a Quality factor score of 76/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Straumann Holding AG in?
Straumann Holding AG (STMN.SW) operates in the Healthcare sector, specifically the Medical Instruments & Supplies industry (Switzerland).